Biomemory Ships DNA Shield, Turning DNA Data Storage into a Commercial Service
Original source
Biomemory Launches DNA Shield, First Commercial Product Built on Its Molecular IT Platform
Dark Reading →Biomemory has launched DNA Shield, a managed service that encodes sensitive digital assets—cryptographic keys, proprietary IP, regulated records—into synthetic DNA and holds them offline under managed custody. The product is positioned as an air-gapped, sovereign layer removed from the network-reachable attack surface, designed to keep critical data recoverable and verifiable over years or decades even as threats from AI advances and quantum computing evolve. Recovery is deliberately a controlled, triggered process rather than routine self-service access. The company has opened an Early Access Program for organizations wanting this offline protection tier.
The launch caps a year of consolidation. In March 2026, Biomemory acquired the assets of Catalog Technologies, the Boston-based DNA data storage pioneer, gaining a second production hub and expanded intellectual property. In July, it appointed Laurent Guengant, a storage and telecom executive with over 30 years in global business leadership, as CEO to drive the shift from research toward commercial deployment. Spun out of Sorbonne University and CNRS, Biomemory now operates production facilities in both Paris and Boston.
DNA Shield is the first product on what the company calls its Molecular IT roadmap. Beyond sovereign data protection, the stated plan extends into broader DNA-based storage from 2029, with molecular search and compute layers to follow. The company co-chairs the DNA Data Storage Alliance and frames the launch as the transition from proving the underlying science to delivering something customers can rely on operationally.
Read the full article
Continue reading at Dark Reading →This is an AI-generated summary. Read the original for the full story.